A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy

Trial Profile

A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms REPEAT
  • Sponsors Roche
  • Most Recent Events

    • 05 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 26 Apr 2009 Post-hoc analysis reported at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 21 Apr 2009 Full results published in Annals of Internal Medicine, 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top